Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference
|Date:||Tuesday, May 21, 2019|
|Time:||3:05 p.m. Eastern Daylight Time|
|Location:||InterContinental New York Barclay, NYC|
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
Osmotica has a late‑stage development pipeline highlighted by two NDA candidates that recently completed Phase III clinical trials: arbaclofen extended‑release tablets for spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.
Osmotica has operations in
Investor and Media Relations for
In-Site Communications, Inc.
Source: Osmotica Holdings US LLC